WO2005077887A1 - Nouveau procede de synthese et nouvelle forme cristalline de l’agomelatine ainsi que les compositions pharmaceutiques qui la contiennent - Google Patents
Nouveau procede de synthese et nouvelle forme cristalline de l’agomelatine ainsi que les compositions pharmaceutiques qui la contiennent Download PDFInfo
- Publication number
- WO2005077887A1 WO2005077887A1 PCT/FR2005/000327 FR2005000327W WO2005077887A1 WO 2005077887 A1 WO2005077887 A1 WO 2005077887A1 FR 2005000327 W FR2005000327 W FR 2005000327W WO 2005077887 A1 WO2005077887 A1 WO 2005077887A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- synthesis
- reaction
- agomelatine
- Prior art date
Links
- TWJHYGPECDXERA-UHFFFAOYSA-N COC1=CC=C2C=CC=C(CCNCCc3cccc(cc4)c3cc4OC)C2C1 Chemical compound COC1=CC=C2C=CC=C(CCNCCc3cccc(cc4)c3cc4OC)C2C1 TWJHYGPECDXERA-UHFFFAOYSA-N 0.000 description 1
- MGJHVZKRAOYORH-UHFFFAOYSA-N COc1ccc(CCC=C2CC#N)c2c1 Chemical compound COc1ccc(CCC=C2CC#N)c2c1 MGJHVZKRAOYORH-UHFFFAOYSA-N 0.000 description 1
- GABLTKRIYDNDIN-UHFFFAOYSA-N COc1ccc(CCCC2=O)c2c1 Chemical compound COc1ccc(CCCC2=O)c2c1 GABLTKRIYDNDIN-UHFFFAOYSA-N 0.000 description 1
- PYJMGUQHJINLLD-UHFFFAOYSA-N COc1ccc(cccc2CC#N)c2c1 Chemical compound COc1ccc(cccc2CC#N)c2c1 PYJMGUQHJINLLD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F03—MACHINES OR ENGINES FOR LIQUIDS; WIND, SPRING, OR WEIGHT MOTORS; PRODUCING MECHANICAL POWER OR A REACTIVE PROPULSIVE THRUST, NOT OTHERWISE PROVIDED FOR
- F03D—WIND MOTORS
- F03D9/00—Adaptations of wind motors for special use; Combinations of wind motors with apparatus driven thereby; Wind motors specially adapted for installation in particular locations
- F03D9/008—Adaptations of wind motors for special use; Combinations of wind motors with apparatus driven thereby; Wind motors specially adapted for installation in particular locations the wind motor being combined with water energy converters, e.g. a water turbine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F03—MACHINES OR ENGINES FOR LIQUIDS; WIND, SPRING, OR WEIGHT MOTORS; PRODUCING MECHANICAL POWER OR A REACTIVE PROPULSIVE THRUST, NOT OTHERWISE PROVIDED FOR
- F03B—MACHINES OR ENGINES FOR LIQUIDS
- F03B13/00—Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates
- F03B13/12—Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates characterised by using wave or tide energy
- F03B13/26—Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates characterised by using wave or tide energy using tide energy
- F03B13/264—Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates characterised by using wave or tide energy using tide energy using the horizontal flow of water resulting from tide movement
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
- F05B—INDEXING SCHEME RELATING TO WIND, SPRING, WEIGHT, INERTIA OR LIKE MOTORS, TO MACHINES OR ENGINES FOR LIQUIDS COVERED BY SUBCLASSES F03B, F03D AND F03G
- F05B2220/00—Application
- F05B2220/30—Application in turbines
- F05B2220/32—Application in turbines in water turbines
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
- F05B—INDEXING SCHEME RELATING TO WIND, SPRING, WEIGHT, INERTIA OR LIKE MOTORS, TO MACHINES OR ENGINES FOR LIQUIDS COVERED BY SUBCLASSES F03B, F03D AND F03G
- F05B2220/00—Application
- F05B2220/70—Application in combination with
- F05B2220/706—Application in combination with an electrical generator
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E10/00—Energy generation through renewable energy sources
- Y02E10/20—Hydro energy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E10/00—Energy generation through renewable energy sources
- Y02E10/30—Energy from the sea, e.g. using wave energy or salinity gradient
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E10/00—Energy generation through renewable energy sources
- Y02E10/70—Wind energy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E10/00—Energy generation through renewable energy sources
- Y02E10/70—Wind energy
- Y02E10/72—Wind turbines with rotation axis in wind direction
Definitions
- the present invention relates to a process for the industrial synthesis of agomelatine or N- [2- (7-methoxy-1-naphthyl) ethyl] acetamide of formula (I):
- the present invention also relates to the crystalline form II of agomelatine, its method of preparation and the pharmaceutical compositions containing it.
- EP 0 447 285 discloses the eight-step access to agomelatine from 7-methoxy-1-tetralone with an average yield of less than 30%.
- This process involves the action of ethyl bromoacetate, followed by aromatization and saponification to yield the corresponding acid, which is then converted to acetamide and then dehydrated to yield (7-methoxy-1-naphthyl) acetonitrile, followed by reduction and then condensation of the acetyl chloride.
- the present invention relates to a process for the industrial synthesis of the compound of formula (I):
- R and R ' which are identical or different, each represent a linear or branched (C 3 -C ⁇ 0 ) alkyl group, an unsubstituted or substituted aryl group or an aryl (C ⁇ -C 6 ) linear or branched unsubstituted arylalkyl group or substituted,
- aryl means a phenyl, naphthyl or biphenyl group
- substituted for the terms "aryl” and “arylalkyl” means that the aromatic portion of these groups may be substituted with 1 to 3 groups, identical or different, selected from alkyl (C ⁇ -C6) linear or branched, hydroxy, and alkoxy (C ⁇ -C6) linear or branched
- the water formed is removed by distillation. It is preferable to use a reaction solvent having a boiling point greater than or equal to that of water and even more preferably forming an azeotrope with water, for example xylene, toluene, anisole or ethylbenzene. tetrachlorethylene, cyclohexene, or mesitylene.
- the conversion reaction of the compound of formula (III) into a compound of formula (NI) is carried out at reflux of toluene or xylene and more preferably at reflux of toluene.
- one of the groups R or R 'of the catalyst used is a linear or branched (C 3 -C ⁇ o) alkyl group, and the other represents an aryl or arylalkyl group. More particularly, a preferred catalyst is that of formula (V a ):
- R ' a represents a phenyl group which is unsubstituted or substituted by one or more linear or branched (C ⁇ -C 6 ) alkyl groups, n is 0 or 1, and R a represents a linear (C 3 -C ⁇ 0 ) alkyl group.
- R ' a represents an unsubstituted phenyl group o. substituted and more particularly an unsubstituted phenyl group.
- the R group is preferred to a hexyl group.
- n 1
- the preferred catalyst used in the reaction of transformation of the compound of Zformula (III) into a compound of formula (VI) according to the process of the invention is benzylammonium heptanoate of formula (IX):
- the compound of formula (VI) is obtained after filtration and washing with an organic or inorganic basic solution such as NaOH, KOH, Ca (OH) 2 , Sr (OH) 2 , or NH 4 OH, and more preferably with a solution of 'sodium hydroxide.
- an organic or inorganic basic solution such as NaOH, KOH, Ca (OH) 2 , Sr (OH) 2 , or NH 4 OH, and more preferably with a solution of 'sodium hydroxide.
- the conversion reaction of the compound of formula (VI) into a compound of formula (VII) is carried out at reflux of toluene or xylene and more preferably at reflux of toluene.
- the catalyst preferably used in the reaction of conversion of the compound of formula (VI) into a compound of formula (VII) is a catalyst in oxide or supported form, for example palladium, platinum, nickel, Al 2 O 3 and more particularly palladium.
- palladium on charcoal more particularly palladium on charcoal 1 to 20% and even more particularly 5% or 10%.
- palladium on charcoal will be used in catalytic amounts, more particularly in amounts ranging from 1 to 10% by weight of catalyst relative to the weight of substrate and more preferably 5%.
- the hydrogen acceptor used preferentially in the conversion reaction of the compound of formula (VI) into a compound of formula (VIT) is an allylic derivative and more particularly an allyl acrylate or an allylglycidylether.
- the preferred allyl acrylate of the process according to the invention is allyl methacrylate.
- the conversion reaction of the compound of formula (VII) into a compound of formula (VIII) according to the process of the invention is carried out between 20 and 40 ° C. and more preferably between 30 and 40 ° C., and even more advantageously at 40 ° C.
- the conversion reaction of the compound of formula (VIII) into a compound of formula (I) is carried out in an alcoholic medium and more particularly in an ethanolic medium.
- the degree of conversion of the compound of formula (III) into a compound of formula (VI) obtained is very high, greater than 97%, unlike what could be observed with the use of acetic acid for which this level does not exceed not 75%.
- the compound of formula (NI) obtained according to the process of the invention is new and is useful as an intermediate for the synthesis of agomelatine in which it is subjected to an aromatization reaction followed by a reduction reaction then coupling with acetic anhydride.
- the invention also extends to the crystalline form II of the agomelatine obtained according to the method described above. It is indeed important to be able to obtain a well-defined and perfectly reproducible crystalline form.
- the present invention relates to the crystalline form II of agomelatine, characterized by the following parameters, obtained from the powder diagram made on Bruker AXS high-resolution D8 diffractometer with an angular range of 3 ° -90 ° in 2 ⁇ , a step of 0.01 ° and 30 s in steps:
- the shape thus obtained is sufficiently stable to allow its prolonged storage without particular conditions of temperature, light, humidity or oxygen content.
- the pharmacological study of the form thus obtained has shown an important activity on the central nervous system as well as microcirculation which makes it possible to establish its utility in the treatment of stress, sleep disorders, anxiety, depression. major, seasonal depressions, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jet lag, schizophrenia, panic attacks, melancholy, appetite disorders, obesity, insomnia, pain, psychotic disorders, epilepsy, diabetes, Parkmson's disease, senile dementia, various disorders related to normal or pathological aging, migraine, memory loss, Alzheimer's disease, and disorders of the cerebral circulation.
- form II of agomelatine can be used in sexual dysfunctions, that it possesses properties of ovulation inhibitors, immunomodulators and that it is likely to be used in the treatment of cancers.
- the crystalline form II agomelatine will be used preferably in the treatment of major depression, seasonal depression, sleep disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jet lag, disorders appetite and obesity.
- the invention also extends to pharmaceutical compositions containing as active principle crystalline form II of agomelatine with one or more inert, non-toxic and suitable excipients.
- pharmaceutical compositions according to the invention mention may be made more particularly of those which are suitable for oral, parenteral (intravenous or subcutaneous), nasal administration, single or coated tablets, granules, sublingual tablets, capsules, tablets, suppositories, creams, ointments, skin gels, injectables, oral suspensions and chewables.
- the useful dosage is adaptable according to the nature and severity of the condition, the route of administration and the age and weight of the patient. This dosage ranges from 0.1 mg to 1 g per day in one or more doses.
- the examples below illustrate the invention, but do not limit it in any way.
- Step A (7-Methoxy-3,4-dihydro-1-naphthalenyl) acetonitrile
- Step A (7-Methoxy-3,4-dihydro-1-naphthalenyl) acetonitrile
- Example 3 Crystalline Form II of N- [2- (7-Methoxy-1-naphthyl) ethyl] acetamide
- the data was recorded on the Bruker AXS high-resolution D8 diffractometer with the following parameters: an angular range of 3 ° -90 ° in 2 °, a step of
- the N- [2- (7-methoxy-1-naphthyl) ethyl] acetamide powder obtained in Example 1 was deposited on a carrier for transmission mounting.
- the assembly includes a front monochromator (Ge (ll l) crystal) and a solid energy-resolved detector (MXP-Dl, Moxtec-SEPH).
- the compound is well crystallized: the width of the lines at mid-height is of the order of 0.07 ° in 2 ⁇ .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Combustion & Propulsion (AREA)
- Pain & Pain Management (AREA)
- Mechanical Engineering (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Sustainable Development (AREA)
- Urology & Nephrology (AREA)
- Power Engineering (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL166815A IL166815A (en) | 2004-02-13 | 2005-02-10 | Process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0401439A FR2866335B1 (fr) | 2004-02-13 | 2004-02-13 | Nouveau procede de synthese de l'agomelatine |
FR0401439 | 2004-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005077887A1 true WO2005077887A1 (fr) | 2005-08-25 |
Family
ID=34685019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/000327 WO2005077887A1 (fr) | 2004-02-13 | 2005-02-11 | Nouveau procede de synthese et nouvelle forme cristalline de l’agomelatine ainsi que les compositions pharmaceutiques qui la contiennent |
Country Status (41)
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608737B2 (en) | 2007-05-01 | 2009-10-27 | Concert Pharmaceuticasl Inc. | Naphthyl(ethyl)acetamides |
WO2012130837A1 (en) | 2011-03-28 | 2012-10-04 | Ratiopharm Gmbh | Solid agomelatine in non-crystalline form |
CN102875408A (zh) * | 2012-10-09 | 2013-01-16 | 江西同和药业有限责任公司 | 一种阿戈美拉汀的制备方法 |
EP2556824A1 (fr) | 2011-08-10 | 2013-02-13 | Les Laboratoires Servier | Composition pharmaceutique solide pour administration buccale d'agomelatine |
EP2562151A1 (en) | 2011-08-25 | 2013-02-27 | Dr. Reddy's Laboratories Ltd. | Processes for the preparation of agomelatine and its intermediates |
WO2013120463A1 (en) | 2012-02-15 | 2013-08-22 | Zentiva, K.S. | A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine |
CN103319370A (zh) * | 2012-03-21 | 2013-09-25 | 黑龙江福和华星制药集团股份有限公司 | 一种(7-甲氧基-1-萘基)乙腈的制备方法 |
WO2014012571A1 (en) | 2012-07-16 | 2014-01-23 | Ratiopharm Gmbh | Complex of agomelatine and cyclodextrin |
EP2703383A1 (en) | 2012-08-27 | 2014-03-05 | Procos S.p.A. | Process for the preparation of agomelatine |
WO2014096373A1 (en) | 2012-12-21 | 2014-06-26 | Laboratorios Lesvi, S. L. | Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof |
WO2014122405A1 (fr) | 2013-02-08 | 2014-08-14 | Les Laboratoires Servier | Composition pharmaceutique solide pour l'administration buccale d'agomélatine |
EP2810656A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, K.S. | Agomelatine formulations comprising agomelatine in the form of co-crystals |
EP2810647A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
WO2015021949A1 (en) | 2013-08-13 | 2015-02-19 | Zentiva, K.S. | A thermodynamically stable solid solution of agomelatine for use in a pharmaceutical formulation |
WO2015124496A1 (en) | 2014-02-19 | 2015-08-27 | Synthon B.V. | Pharmaceutical composition comprising amorphous agomelatine |
EP3075724A1 (en) | 2015-03-31 | 2016-10-05 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Solid form of agomelatine |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2866334B1 (fr) * | 2004-02-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine |
US7498466B2 (en) * | 2004-02-13 | 2009-03-03 | Les Laboratoires Servier | Process for the synthesis and crystalline form of agomelatine |
US7498465B2 (en) * | 2004-02-13 | 2009-03-03 | Les Laboratoires Servier | Process for the synthesis and crystalline form of agomelatine |
FR2889523B1 (fr) * | 2005-08-03 | 2007-12-28 | Servier Lab | Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
FR2889522B1 (fr) * | 2005-08-03 | 2007-12-28 | Servier Lab | Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
US7635721B2 (en) | 2005-08-03 | 2009-12-22 | Les Laboratoires Servier | Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it |
US7645905B2 (en) | 2005-08-03 | 2010-01-12 | Les Laboratoires Servier | Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it |
FR2889521B1 (fr) * | 2005-08-03 | 2007-12-28 | Servier Lab | Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
US7358395B2 (en) | 2005-08-03 | 2008-04-15 | Les Laboratories Servier | Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it |
FR2890562B1 (fr) * | 2005-09-09 | 2012-10-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime |
FR2894475B1 (fr) * | 2005-12-14 | 2008-05-16 | Servier Lab | Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine |
FR2899472B1 (fr) * | 2006-04-07 | 2008-09-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee |
CN101161638B (zh) * | 2006-10-13 | 2010-09-29 | 北京德众万全药物技术开发有限公司 | 一种新的阿戈美拉汀重要中间体的制备方法 |
FR2908994B1 (fr) * | 2006-11-24 | 2009-04-03 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement de la leucomalacie periventriculaire |
FR2908995B1 (fr) | 2006-11-24 | 2009-02-06 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis |
WO2008141033A1 (en) * | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals Inc. | Substituted naphthalenes |
JP2009013074A (ja) * | 2007-06-30 | 2009-01-22 | Lab Servier | 全般性不安障害の処置を目的とする医薬を得るためのアゴメラチンの使用 |
FR2919606B1 (fr) | 2007-08-03 | 2010-09-17 | Servier Lab | Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine. |
FR2923482B1 (fr) * | 2007-11-09 | 2010-01-29 | Servier Lab | Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
CN101638376B (zh) * | 2008-07-29 | 2011-04-27 | 江苏恩华药业股份有限公司 | 阿戈美拉汀的制备方法及其中间体 |
FR2934857B1 (fr) * | 2008-08-05 | 2010-08-27 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
FR2934856B1 (fr) | 2008-08-05 | 2010-08-13 | Servier Lab | Nouveau procede d'obtention de la forme cristalline v de l'agomelatine |
FR2934859B1 (fr) * | 2008-08-05 | 2010-08-13 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
FR2934855B1 (fr) * | 2008-08-05 | 2010-08-13 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
CN101481321B (zh) * | 2009-02-27 | 2012-04-18 | 上海医药工业研究院 | 阿戈美拉汀卤化氢复合物及其制备方法 |
CN101585779B (zh) * | 2009-03-10 | 2014-04-02 | 上海医药工业研究院 | 阿戈美拉汀的晶型vi及其制备方法和应用 |
WO2011006387A1 (zh) * | 2009-07-11 | 2011-01-20 | 浙江华海药业股份有限公司 | 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法 |
CN102001959B (zh) * | 2009-09-01 | 2014-07-02 | 北京本草天源药物研究院 | 一种药物晶体及其制备方法和用途 |
CN102050756A (zh) * | 2009-11-09 | 2011-05-11 | 北京利乐生制药科技有限公司 | 阿戈美拉汀新晶型及其制备方法 |
EP2319827A1 (en) | 2009-11-09 | 2011-05-11 | Ratiopharm GmbH | Process for the production of polymorph form I of agomelatine |
CN101704763B (zh) * | 2009-11-25 | 2012-03-28 | 天津泰普药品科技发展有限公司 | 阿戈美拉汀i型晶体的制备方法 |
CN101709036B (zh) * | 2009-12-17 | 2012-07-04 | 天津药物研究院 | 阿戈美拉汀中间体2-(7-甲氧基-1-萘基)乙胺的制备 |
TW201139370A (en) | 2009-12-23 | 2011-11-16 | Lundbeck & Co As H | Processes for the manufacture of a pharmaceutically active agent |
CN101781226B (zh) * | 2009-12-23 | 2012-03-28 | 天津泰普药品科技发展有限公司 | 阿戈美拉汀及其药物组合物 |
CN102146046B (zh) * | 2010-02-05 | 2013-07-03 | 天津市汉康医药生物技术有限公司 | 一种n-[2-(7-甲氧基-1-萘基)乙基]乙酰胺新的制备方法 |
FR2956031B1 (fr) * | 2010-02-11 | 2012-03-02 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc) |
CN101792400B (zh) * | 2010-03-16 | 2013-01-30 | 华东师范大学 | 一种阿戈美拉汀的合成方法 |
EP2558440B1 (en) | 2010-04-15 | 2016-11-16 | ratiopharm GmbH | Process for the production of polymorph form i of agomelatine |
CN101870662B (zh) * | 2010-05-21 | 2013-03-20 | 中山大学 | 结晶型阿戈美拉汀溶剂化物及其制备方法 |
CN102276492B (zh) * | 2010-06-08 | 2013-04-10 | 上海医药工业研究院 | 阿戈美拉汀中间体及其制备方法 |
WO2011154140A2 (en) | 2010-06-10 | 2011-12-15 | Gador S.A. | New process for the preparation of n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamide and new crystalline form |
CN102229541A (zh) * | 2010-09-17 | 2011-11-02 | 福建广生堂药业有限公司 | 阿戈美拉汀n-[2-(7-甲氧基萘-1-基)乙基]乙酰胺的制备方法 |
CN102452951B (zh) * | 2010-10-25 | 2014-02-19 | 天津泰普药品科技发展有限公司 | 阿戈美拉汀及其药物组合物 |
CN102030673B (zh) * | 2010-11-24 | 2014-04-23 | 威海迪素制药有限公司 | 一种阿戈美拉汀新晶型及制备方法 |
CN102531956B (zh) * | 2010-12-21 | 2014-07-09 | 浙江九洲药业股份有限公司 | 用于制备阿戈美拉汀的中间体及相关制备方法 |
WO2012093402A1 (en) * | 2011-01-04 | 2012-07-12 | Symed Labs Limited | Processes for the preparation of n-[2-(7-methoxy-1-naphthyl)ethyl]acetamide |
FR2970001B1 (fr) * | 2011-01-05 | 2013-01-04 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
FR2970000B1 (fr) | 2011-01-05 | 2013-01-04 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
CZ303787B6 (cs) | 2011-01-21 | 2013-05-02 | Zentiva, K.S. | Metastabilní krystalové formy agomelatinu a jejich farmaceutické kompozice |
CN102690209A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物 |
CN102690210A (zh) * | 2011-03-23 | 2012-09-26 | 上海医药工业研究院 | 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物 |
WO2012127483A1 (en) * | 2011-03-24 | 2012-09-27 | Symed Labs Limited | Processes for the preparation of intermediates of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide |
FR2976284B1 (fr) * | 2011-06-09 | 2013-05-24 | Servier Lab | Nouveaux co-cristaux d'agomelatine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
PH12012000132A1 (en) | 2011-06-09 | 2014-10-20 | Servier Lab | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |
ITMI20111078A1 (it) | 2011-06-15 | 2012-12-16 | Laboratorio Chimico Int Spa | Procedimento per la preparazione di forme cristalline dell?agomelatina e nuovo polimorfo |
WO2013018100A1 (en) * | 2011-08-01 | 2013-02-07 | Symed Labs Limited | A process for the preparation of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide crystalline form i |
PT2739605E (pt) | 2011-08-03 | 2016-06-20 | Laboratorio Chimico Int S P A | Processo para a preparação da forma cristalina i da agomelatina |
CN102367228A (zh) * | 2011-10-24 | 2012-03-07 | 南京工业大学 | 一种合成阿戈美拉汀的方法 |
EP2771312B1 (en) | 2011-11-30 | 2017-05-31 | ratiopharm GmbH | Agomelatine-urea complex and crystalline forms thereof |
EP2851363B1 (en) | 2012-05-14 | 2018-01-03 | Shanghai Righthand Pharmtech. Co., Ltd. | Agomelatine acid radical composite, and preparation method and application thereof |
CN102838504A (zh) * | 2012-09-12 | 2012-12-26 | 福建广生堂药业股份有限公司 | 一种阿戈美拉汀的新晶型l及其制备方法 |
WO2014056421A1 (zh) * | 2012-10-09 | 2014-04-17 | 江西同和药业有限责任公司 | 1-氰基-1-(7-甲氧基-1-萘基)甲醇酯类化合物及其制备方法和应用 |
EP2909166A4 (en) * | 2012-10-22 | 2016-10-26 | Symed Labs Ltd | PROCESS FOR THE PREPARATION OF AGOMALATIN USING NEW INTERMEDIATES |
WO2014072998A1 (en) | 2012-11-07 | 2014-05-15 | Cadila Healthcare Limited | An improved process for preparation of agomelatine |
CN102942501B (zh) * | 2012-12-10 | 2015-08-19 | 天津泰普药品科技发展有限公司 | 一种氢化制备阿戈美拉汀的生产方法 |
ES2590908T3 (es) | 2012-12-17 | 2016-11-24 | Dr. Reddy's Laboratories Ltd. | Cocristal de agomelatina con ácido fosfórico |
CN104130154A (zh) * | 2013-05-03 | 2014-11-05 | 郭炳华 | 一种制备高纯度阿戈美拉汀的方法 |
WO2015000555A2 (en) * | 2013-07-04 | 2015-01-08 | Pharmathen S.A. | A novel process for the preparation of tetralin and naphthalene derivatives |
FR3014437B1 (fr) * | 2013-12-05 | 2016-12-23 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
FR3014434B1 (fr) | 2013-12-05 | 2015-12-25 | Servier Lab | Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine |
FR3014433B1 (fr) | 2013-12-05 | 2015-12-25 | Servier Lab | Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine |
WO2017005954A1 (es) * | 2015-07-03 | 2017-01-12 | Universidad De Granada | Análogos de la melatonina para el tratamiento del cáncer |
CN105601537B (zh) * | 2016-01-25 | 2018-11-06 | 江西同和药业股份有限公司 | 一种2-(7-甲氧基-1-萘基)乙腈的制备方法 |
CN105669494A (zh) * | 2016-03-11 | 2016-06-15 | 上海韬鸿化工科技有限公司 | 一种2-(7-甲氧基-1-萘基)乙氰的制备方法 |
FR3056211B1 (fr) | 2016-09-19 | 2018-09-07 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
CN106928082A (zh) * | 2016-12-27 | 2017-07-07 | 湖南天济草堂制药股份有限公司 | 一种新的阿戈美拉汀合成及纯化方法 |
CN107162933A (zh) * | 2017-06-19 | 2017-09-15 | 太仓大唐化纤厂 | 一种合成阿戈美拉汀重要中间体7‑甲氧基萘乙腈的方法 |
CN107382773A (zh) * | 2017-06-19 | 2017-11-24 | 太仓弘杉环保科技有限公司 | 一种合成7‑甲氧基萘乙腈的方法 |
EP3466413A1 (en) | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Pharmaceutical composition containing agomelatine and process for the preparation thereof |
EP3466923A1 (en) | 2017-10-09 | 2019-04-10 | KRKA, d.d., Novo mesto | Process for the preparation of agomelatine in crystalline form |
EP4342879A1 (en) | 2022-09-21 | 2024-03-27 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Very efficient process for the preparation of agomelatine |
CN117776934A (zh) * | 2023-12-22 | 2024-03-29 | 江苏威奇达药业有限公司 | 一种阿戈美拉汀中间体的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3931188A (en) * | 1974-05-06 | 1976-01-06 | Bristol-Myers Company | 3-Hydroxy-5,6-benzomorphinan derivatives |
US3992403A (en) * | 1975-05-30 | 1976-11-16 | Schering Corporation | 2-Imidazolines and their use as hypoglycemic agents |
EP0447285A1 (fr) * | 1990-02-27 | 1991-09-18 | Adir Et Compagnie | Nouveaux dérivés à structure naphtalénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4327022A (en) * | 1973-08-16 | 1982-04-27 | Sterling Drug Inc. | Heterocyclic alkyl naphthols |
FR2737725B1 (fr) * | 1995-08-08 | 1997-10-31 | Valentonine | Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament |
WO2005063297A2 (en) * | 2003-12-24 | 2005-07-14 | Sepracor Inc. | Melatonin combination therapy for improving sleep quality |
-
2004
- 2004-02-13 FR FR0401439A patent/FR2866335B1/fr not_active Expired - Fee Related
-
2005
- 2005-02-03 CA CA002495967A patent/CA2495967C/fr active Active
- 2005-02-07 MY MYPI20050476A patent/MY138452A/en unknown
- 2005-02-07 US US11/052,630 patent/US7250531B2/en active Active
- 2005-02-07 SG SG200500677A patent/SG114703A1/en unknown
- 2005-02-07 AP AP2005003221A patent/AP1839A/xx active
- 2005-02-10 MX MXPA05001637A patent/MXPA05001637A/es active IP Right Grant
- 2005-02-10 CR CR7680A patent/CR7680A/es unknown
- 2005-02-10 IL IL166815A patent/IL166815A/en active IP Right Grant
- 2005-02-11 NZ NZ538191A patent/NZ538191A/en unknown
- 2005-02-11 ZA ZA2005/01257A patent/ZA200501257B/en unknown
- 2005-02-11 ME MEP-2008-552A patent/ME01364B/me unknown
- 2005-02-11 PT PT05290308T patent/PT1564202E/pt unknown
- 2005-02-11 GE GEAP8625A patent/GEP20074133B/en unknown
- 2005-02-11 SI SI200530417T patent/SI1564202T1/sl unknown
- 2005-02-11 RS RSP-2008/0552A patent/RS50662B/sr unknown
- 2005-02-11 MA MA28101A patent/MA27518A1/fr unknown
- 2005-02-11 ES ES05290308T patent/ES2314588T3/es active Active
- 2005-02-11 PL PL05290308T patent/PL1564202T3/pl unknown
- 2005-02-11 AT AT05290308T patent/ATE407921T1/de active
- 2005-02-11 UA UAA200501277A patent/UA78825C2/uk unknown
- 2005-02-11 AU AU2005200616A patent/AU2005200616B8/en active Active
- 2005-02-11 EP EP05290308A patent/EP1564202B1/fr active Active
- 2005-02-11 UY UY28747A patent/UY28747A1/es active IP Right Grant
- 2005-02-11 NO NO20050741A patent/NO333500B1/no unknown
- 2005-02-11 WO PCT/FR2005/000327 patent/WO2005077887A1/fr active Application Filing
- 2005-02-11 DE DE602005009585T patent/DE602005009585D1/de active Active
- 2005-02-11 DK DK05290308T patent/DK1564202T3/da active
- 2005-02-11 AR ARP050100502A patent/AR047741A1/es active IP Right Grant
- 2005-02-12 KR KR1020050011747A patent/KR100692776B1/ko active Protection Beyond IP Right Term
- 2005-02-12 SA SA05260001A patent/SA05260001B1/ar unknown
- 2005-02-14 EC EC2005005601A patent/ECSP055601A/es unknown
- 2005-02-14 BR BRPI0500393A patent/BRPI0500393B8/pt active IP Right Grant
- 2005-02-14 EA EA200500203A patent/EA008473B1/ru unknown
- 2005-02-14 CU CU20050032A patent/CU23515A3/es active IP Right Grant
- 2005-02-14 BR BR122018068717A patent/BR122018068717B8/pt active IP Right Grant
- 2005-02-14 JP JP2005035758A patent/JP4316517B2/ja active Active
- 2005-02-16 CN CN200710096437XA patent/CN101041629B/zh active Active
- 2005-02-16 CN CNB2005100716116A patent/CN1321106C/zh active Active
- 2005-11-21 HK HK05110484A patent/HK1078563A1/xx unknown
-
2006
- 2006-06-06 TW TW095120045A patent/TW200716511A/zh unknown
-
2007
- 2007-04-06 US US11/784,484 patent/US7544839B2/en active Active
- 2007-11-15 HK HK07112471.6A patent/HK1107081A1/xx unknown
-
2008
- 2008-10-23 CY CY20081101191T patent/CY1108445T1/el unknown
- 2008-11-25 HR HR20080537T patent/HRP20080537T3/xx unknown
-
2010
- 2010-08-04 AU AU2010207746A patent/AU2010207746B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3931188A (en) * | 1974-05-06 | 1976-01-06 | Bristol-Myers Company | 3-Hydroxy-5,6-benzomorphinan derivatives |
US3992403A (en) * | 1975-05-30 | 1976-11-16 | Schering Corporation | 2-Imidazolines and their use as hypoglycemic agents |
EP0447285A1 (fr) * | 1990-02-27 | 1991-09-18 | Adir Et Compagnie | Nouveaux dérivés à structure naphtalénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
Non-Patent Citations (2)
Title |
---|
DEPREUX P ET AL: "SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS OF NOVEL NAPHTHALENIC AND BIOISOSTERIC AMIDIC DERIVATIVES AS MELATONIN RECEPTOR LIGANDS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 20, 30 September 1994 (1994-09-30), pages 3231 - 3239, XP002016146, ISSN: 0022-2623 * |
TINANT, BERNARD ET AL: "N-[2-(7-Methoxy-1-naphthyl)ethyl]acetamide, a potent melatonin analog", ACTA CRYSTALLOGRAPHICA, SECTION C: CRYSTAL STRUCTURE COMMUNICATIONS , C50(6), 907-10 CODEN: ACSCEE; ISSN: 0108-2701, 1994, XP009047983 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608737B2 (en) | 2007-05-01 | 2009-10-27 | Concert Pharmaceuticasl Inc. | Naphthyl(ethyl)acetamides |
WO2012130837A1 (en) | 2011-03-28 | 2012-10-04 | Ratiopharm Gmbh | Solid agomelatine in non-crystalline form |
MD20120062A3 (ro) * | 2011-08-10 | 2016-06-30 | Les Laboratoires Servier | Compoziţie farmaceutică solidă de agomelatină pentru administrare bucală |
EP2556824A1 (fr) | 2011-08-10 | 2013-02-13 | Les Laboratoires Servier | Composition pharmaceutique solide pour administration buccale d'agomelatine |
WO2013021139A1 (fr) | 2011-08-10 | 2013-02-14 | Les Laboratoires Servier | Composition pharmaceutique solide pour administration buccale d'agomelatine |
EP2562151A1 (en) | 2011-08-25 | 2013-02-27 | Dr. Reddy's Laboratories Ltd. | Processes for the preparation of agomelatine and its intermediates |
WO2013120463A1 (en) | 2012-02-15 | 2013-08-22 | Zentiva, K.S. | A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine |
CN103319370A (zh) * | 2012-03-21 | 2013-09-25 | 黑龙江福和华星制药集团股份有限公司 | 一种(7-甲氧基-1-萘基)乙腈的制备方法 |
CN103319370B (zh) * | 2012-03-21 | 2016-08-03 | 黑龙江福和华星制药集团股份有限公司 | 一种(7-甲氧基-1-萘基)乙腈的制备方法 |
WO2014012571A1 (en) | 2012-07-16 | 2014-01-23 | Ratiopharm Gmbh | Complex of agomelatine and cyclodextrin |
EP2703383A1 (en) | 2012-08-27 | 2014-03-05 | Procos S.p.A. | Process for the preparation of agomelatine |
CN102875408A (zh) * | 2012-10-09 | 2013-01-16 | 江西同和药业有限责任公司 | 一种阿戈美拉汀的制备方法 |
WO2014096373A1 (en) | 2012-12-21 | 2014-06-26 | Laboratorios Lesvi, S. L. | Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof |
WO2014122405A1 (fr) | 2013-02-08 | 2014-08-14 | Les Laboratoires Servier | Composition pharmaceutique solide pour l'administration buccale d'agomélatine |
EP2810647A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
WO2014194992A1 (en) | 2013-06-06 | 2014-12-11 | Zentiva, K.S. | Agomelatine formulations comprising agomelatine in the form of co-crystals |
WO2014194991A1 (en) | 2013-06-06 | 2014-12-11 | Zentiva, K.S. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
EP2810656A1 (en) | 2013-06-06 | 2014-12-10 | Zentiva, K.S. | Agomelatine formulations comprising agomelatine in the form of co-crystals |
WO2015021949A1 (en) | 2013-08-13 | 2015-02-19 | Zentiva, K.S. | A thermodynamically stable solid solution of agomelatine for use in a pharmaceutical formulation |
WO2015124496A1 (en) | 2014-02-19 | 2015-08-27 | Synthon B.V. | Pharmaceutical composition comprising amorphous agomelatine |
EP3075724A1 (en) | 2015-03-31 | 2016-10-05 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Solid form of agomelatine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1564202B1 (fr) | Nouveau procédé de synthèse et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent | |
CA2495960C (fr) | Nouveau procede de synthese du (7-methoxy-1-naphtyl)acetonitrile et application a la synthese de l'agomelatine | |
EP1564204B1 (fr) | Nouveau procédé de synthese du (7-methoxy-3,4-dihydro-1-naphtalenyl) acetonitrile et application à la synthese de l' aglomelatine | |
EP2151427A1 (fr) | Nouveau procédé de synthése de l'agomélatine | |
EP2151428A1 (fr) | Nouveau procédé de synthèse de l'agomélatine | |
US7498465B2 (en) | Process for the synthesis and crystalline form of agomelatine | |
EP2151429B1 (fr) | Nouveau procédé de synthèse de l'agomélatine | |
EP1564205B1 (fr) | Nouveau procédé de synthèse du (7-méthoxy-1-naphtyl) acétonitrile et application à la synthèse de l'agomélatine | |
US7498466B2 (en) | Process for the synthesis and crystalline form of agomelatine | |
OA12900A (fr) | Nouveau procédé de synthèse et nouvelle forme crystalline de l'agomélatine ainsi que les compositions pharmaceutiques qui la contiennent. | |
TW200927710A (en) | New crystalline form and process for the synthesis of agomelatine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |